Exagen Inc. - Common Stock (XGN)
Frequently Asked Questions About Exagen Inc. - Common Stock (XGN)
Does Exagen Inc. have any partnerships or collaborations?
Exagen Inc. actively pursues partnerships and collaborations with healthcare organizations, research institutions, and other biotech companies to expand its reach and enhance its product offerings. These collaborations often focus on advancing research, improving clinical trial designs, and jointly developing diagnostic innovations.
Has Exagen Inc. received any awards or recognitions?
Exagen Inc. has received various accolades and recognitions for its innovative contributions to the field of autoimmune diagnostics. This includes industry awards for its AVISE product line and acknowledgments in biotechnology publications that highlight advances in diagnostic technology aimed at improving patient outcomes.
How can investors learn more about Exagen Inc.?
Investors can learn more about Exagen Inc. through its official website, which provides comprehensive information about the company's products, financial performance, and corporate news. Additionally, interested parties can access annual reports, investor presentations, and SEC filings that offer insights into Exagen's operations and market strategies.
How does Exagen Inc. contribute to research and development?
Exagen Inc. invests significantly in research and development (R&D) to discover new diagnostic solutions and enhance existing products. This involves collaborations with academic institutions and clinical research centers to advance the understanding of autoimmune diseases and increase the efficacy of their diagnostic tools.
How does Exagen Inc. envision its growth in the future?
Exagen Inc. envisions growth through the expansion of its product portfolio, increased market penetration, and continuous innovation in diagnostic testing for autoimmune diseases. The company aims to broaden its footprint in the diagnostics market while improving healthcare outcomes for patients through precise and timely testing solutions.
How does Exagen Inc. handle regulatory compliance?
Exagen Inc. adheres to stringent regulatory standards to ensure the safety and effectiveness of its diagnostic products. The company works closely with regulatory agencies, such as the U.S. Food and Drug Administration (FDA), to navigate compliance and approval processes, which bolster the trust and credibility of its offerings in the healthcare marketplace.
Is Exagen Inc. publicly traded?
Yes, Exagen Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol 'XGN'. As a publicly traded company, Exagen is subject to regulatory requirements and disclosure practices designed to provide transparency and information to its shareholders and the public.
What are the financial highlights of Exagen Inc.?
As of the latest financial reports, Exagen Inc. has shown incremental revenue growth attributed to the increasing adoption of its AVISE tests and new product launches. Investors and analysts closely monitor the company’s financial performance, including revenue, net income, and growth projections within the burgeoning field of autoimmune diagnostics.
What are the main products offered by Exagen Inc.?
Exagen Inc. offers several diagnostic products, with its flagship product being the AVISE® test platform. This includes AVISE® Lupus, which assesses specific biomarkers associated with lupus and helps physicians make informed decisions about patient care and treatment. The company also has a suite of related tests designed for other autoimmune conditions.
What are the potential risks facing Exagen Inc.?
As with any biotechnology company, Exagen Inc. faces potential risks that include regulatory hurdles, market competition, and the need for ongoing research and development investment. Additionally, reliance on specific diseases for market demand can create vulnerabilities in its business model, necessitating strategic planning and adaptability.
What does Exagen Inc. do?
Exagen Inc. is a biotechnology company focused on developing and commercializing products for the diagnosis and management of autoimmune diseases, particularly lupus and other related conditions. The company leverages proprietary technology to provide diagnostic solutions that aid in the assessment of these diseases, helping patients and healthcare professionals take informed decisions regarding treatment options.
What is AVISE® Lupus?
AVISE® Lupus is a proprietary diagnostic test developed by Exagen Inc. that helps evaluate patients for lupus by measuring certain biomarkers and antibodies associated with the disease. The test aims to provide healthcare providers with accurate information that can guide diagnosis, monitoring, and treatment decisions for patients suspected of having lupus.
What is Exagen Inc.'s mission statement?
Exagen Inc.'s mission is to empower healthcare professionals and patients with accurate and actionable diagnostic information that enables early detection, effective management, and improved outcomes for those living with autoimmune diseases. The company is committed to advancing innovative solutions in personalized medicine.
What is the competitive landscape for Exagen Inc.?
The competitive landscape for Exagen Inc. includes other biotechnology and diagnostic companies focused on autoimmune diseases. The market is dynamic, with several players offering similar tests and services. Exagen differentiates itself through its proprietary technology and a strong emphasis on the clinical utility of its products.
What is the significance of the company's ticker symbol, XGN?
The ticker symbol 'XGN' represents Exagen Inc. on the NASDAQ stock exchange. Companies use ticker symbols as a unique identifier for their shares, allowing investors and traders to easily locate and trade a company's stock on the market.
What role does technology play in Exagen Inc.'s offerings?
Technology plays a crucial role in Exagen Inc.’s diagnostic offerings, particularly through the utilization of advanced biomarker assays and proprietary algorithms. These technologies enable the company to deliver reliable, reproducible, and clinically relevant diagnostic information that aids providers in making informed decisions about patient care.
When was Exagen Inc. founded?
Exagen Inc. was founded in 2018. Since its establishment, the company has focused on advancing personalized medicine with a specific emphasis on autoimmune disorders, building a portfolio of diagnostic tests that support clinicians in their management of patients.
Where is Exagen Inc. headquartered?
Exagen Inc. is headquartered in San Diego, California. This strategic location provides the company access to a vibrant biotech community, as well as proximity to leading research institutions and healthcare professionals in the field of autoimmune disease.
Who are the key leaders and executives at Exagen Inc.?
Exagen Inc. is led by a team of experienced executives with extensive backgrounds in biotechnology, healthcare, and business management. The leadership team includes experts in clinical development, operational management, and marketing, who collectively drive the company's strategic vision and operational goals.
Who is the target market for Exagen Inc.'s products?
The target market for Exagen Inc. comprises healthcare providers and medical professionals specializing in rheumatology and autoimmune diseases. Additionally, the company aims to reach patients with suspected or diagnosed autoimmune conditions, especially lupus, who may benefit from more precise diagnostic insights.
What is the current price of Exagen Inc. - Common Stock?
The current price of Exagen Inc. - Common Stock is 3.980
When was Exagen Inc. - Common Stock last traded?
The last trade of Exagen Inc. - Common Stock was at 4:00 pm EDT on May 11th, 2026
What is the market capitalization of Exagen Inc. - Common Stock?
The market capitalization of Exagen Inc. - Common Stock is 64.18M
How many shares of Exagen Inc. - Common Stock are outstanding?
Exagen Inc. - Common Stock has 16.13M shares outstanding.